Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
Liposomes that are less than nm in
2022-06-07
Liposomes that are less than 200nm in diameter are necessary to optimize uptake of liposomes by Aprepitant (Oesterling et al., 2014). The liposomes constructed in these experiments were found to be sufficiently small in diameter for use in in vivo and in vitro experiments. Even smaller diameters are
-
br Histamine H R Many of the
2022-06-07
Histamine H3R Many of the highlight H3R ligands have been described as suitable pharmacological tools for in vitro or in vivo studies and are designated here. The number of ligands and structural categories is huge, and a number of inclusive reviews of the SAR and properties of H3R ligands have b
-
Conflicting data concerning the involvement
2022-06-07
Conflicting data concerning the involvement of H2R on glycaemia has also arisen. Its antagonism was reported to decrease [35], not affect [36], [37] and increase [38], [39] BTL105 receptor levels. In comparison, the clinical experience with antipsychotic drugs generated clearer evidence for the inv
-
MK-0822 With LML methyl oxo dihydropyridazin yl piperidin yl
2022-06-07
With LML-134 (1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate) containing drug-likeness properties (MW 375.47, five HBA, and MLogP 1.88), Novartis presents an additional drug-candidate to treat excessive sleepiness. A phase I clinical study was perform
-
A complimentary approach with Per Luc cells exposed
2022-06-07
A complimentary approach with Per2:Luc Proteinase K exposed to hypoxia as well as with mBmal1:Luc circadian reporter cells in which we overexpressed variants of HIF-1α and HIF-2α revealed that hypoxia and HIFs can not only shorten the period but also decrease the amplitude of the clock (Figures 2 an
-
The first wave of cells infiltrating
2022-06-07
The first wave of Luciferase Reporter Assay Kit infiltrating heart shortly after MI is composed mainly of neutrophils, with the highest number on the first day after ischemic episode [101]. These cells are recruited via C-X-C motif chemokine ligand-2 (CXCL-2)- and CXCL-5-mediated chemotaxis. Both c
-
The selection of mutations in vivo with antivirals is a
2022-06-07
The selection of mutations in vivo with antivirals is a complex process involving, among other things, the frequency of a given mutation prior to treatment, the effect of that mutation on viral protein function, and the interplay of a given mutation pattern with host immune mechanisms. Investigation
-
The LOD and linear range
2022-06-07
The LOD and linear range of the cobas HBV test using the cobas 4800 system in this study were similar to those provided by the manufacturer. We found a strong correlation between the results of the cobas HBV test and CAP/CTM v2.0 systems; however, 7.7% of samples yielded detectable results only with
-
AZD1152-HQPA Over the last years numerous studies
2022-06-07
Over the last 15 years, numerous studies gave insights into sGC activation and binding of activators: Photoaffinity labelling studies with cinaciguat suggested the N-terminus of the β1 subunit as target region for this new drug [17]. Schmidt et al. identified the amino acids tyrosine 135, serine 137
-
The first report of GUCY D
2022-06-07
The first report of GUCY2D-related gene augmentation therapy in mammalians was also reported in 2006 in the KO mouse model (section 4.1.1). In this study, an AAV5 vector by using AAV5-mediated transfer of the bovine cDNA (the same used in the chicken study) was injected to the post-natal KO retina a
-
The GPR gene was included in our
2022-06-07
The GPR35 gene was included in our survey because of its location immediately 3′ to CAPN10 and because it showed evidence of association with type 2 diabetes. Also, its expression in tissues including pancreatic islets and skeletal muscle is consistent with a possible role in type 2 diabetes. Our re
-
Acknowledgements br Introduction The neurotransmitter glycin
2022-06-06
Acknowledgements Introduction The neurotransmitter glycine acts through two receptors: a strychnine-sensitive glycine receptor (GlyA) and a strychnine-insensitive glycine receptor (GlyB). GlyA is localized to the neuronal membrane post-synaptic to inhibitory glycinergic neurons, whereas GlyB is
-
To date glycine receptors have been
2022-06-06
To date, glycine receptors have been found in five distinct transmembrane protein subunits (one β subunit and four α subunit (α1–α4)), combining to form two different types of functional receptors [4], [14], either α homomeric, the immature extrasynaptic glycine receptor subtype, or αβ heteromeric,
-
Ion dependence of mGluRs activity has been
2022-06-06
Ion dependence of mGluRs activity has been previously reported, notably to Ca2+ and Cl− (Kuang and Hampson, 2006). While mGlu1 and mGlu3 receptors were demonstrated to be sensitive to Ca2+, Cl− modulation was reported for all mGluRs, with a lesser extent for the mGlu2 receptor (DiRaddo et al., 2014;
-
br Methods GLUT DS was diagnosed either when analysis
2022-06-06
Methods GLUT1DS was diagnosed either when analysis of the SLC2A1 gene showed a pathogenic mutation and/or when cerebrospinal fluid (CSF) analysis met the criteria for GLUT1DS: a CSF Triamcinolone below the 10th percentile, a cerebrospinal fluid (CSF) to blood ratio below the 25th percentile and
14434 records 390/963 page Previous Next First page 上5页 386387388389390 下5页 Last page